Search Results - hiv

36 Results

Sort By:

Improved HIV Vaccines Through Ras Activation

Abstract: Researchers at the National Cancer Institute (NCI) have developed a new method of improving the efficacy of vaccines in patients with human immunodeficiency virus (HIV) by activating Ras. This method can be used to develop more efficacious vaccine compositions by activating Ras before, during, or after vaccination. Additionally, the researchers...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Rafick Sakaly, Slim Fourati, Mark Cameron, Monica Vaccari, Luca Schifanella, Shari Gordon, Melvin Doster, Namal Liyanage

Keywords(s): Franchini, HIV, Human Immunodeficiency Virus, immune response, RAS, Ras Pathway Activation

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

High Efficacy Vaccine and Microbicide Combination For Use Against HIV

Abstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Marjorie Robert-Guroff, Daniel Appella, Sabrina Helmold Hait, Mohammed Rahman, Massimiliano Bissa, Ettore Appella, Lisa Marie Jenkins, Isabela Silva De Castro

Keywords(s): Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Vaccines

Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics

Abstract: The subject invention describes a new class of compounds (such as peptides or mimetics) that target viral RNAs and inhibit the viral life cycle by blocking the viral recognition process. More specifically, these compounds are the first against an RNA Target - currently there are no clinical drugs against RNA targets in the treatment of any...

Published: 4/8/2024 | Inventor(s): Yun-Xing Wang, Liu Yu, Ping Yu, Ina O'Carroll

Keywords(s): Anti-Viral, HIV

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Anti-Viral Compounds that Inhibit HIV Activity

Abstract: Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity. Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses...

Published: 4/8/2024 | Inventor(s): John Beutler, Jian-kang Jiang, Suhman Chung, Craig Thomas, Stuart LeGrice, Jennifer Wilson

Keywords(s): AIDS, HIV, ribonuclease H, RNase H, tropolone derivative, viral replication

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Scytovirin Domain 1 Related Polypeptides

Abstract: Despite therapeutic advances, human immunodeficiency virus (HIV) is still a pervasive disease, with approximately 37 million people infected worldwide. Peptides have become popular therapeutic agents, as these proteins offer structural diversity for many different diseases. Several peptides were commercially developed as HIV therapeutics,...

Published: 4/8/2024 | Inventor(s): Barry O'Keefe, Chang-yun Xiong, James McMahon, R. Andrew Byrd

Keywords(s): HIV, O’Keefe, POLYPEPTIDES, Scytovirin

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Application > Therapeutics

HIV-1 IN Mutant in a Single Round Vector

Abstract: Antiretroviral therapy (ART) has changed the prognosis of HIV-1 infection to a chronic illness that, in most cases, can be managed or controlled. Integrase strand transfer inhibitors (INSTIs) and reverse transcription inhibitors are essential components of ART drug cocktails. In compliant individuals, ART has been found to block viral replication...

Published: 4/8/2024 | Inventor(s): Steven Smith, Stephen Hughes

Keywords(s): Anti-HIV Drugs, HIV, Hughes, INSTIs, Integrase Strand Transfer Inhibitors, pNL4.3, Reverse Transcriptase, RT, Single-Round Vectors, Smith

Category(s): Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

HIV-1 Therapeutic Inhibits Viral Entry

Abstract: Soluble forms (sCD4) of human CD4, the HIV-1 primary receptor, are potent HIV-1 entry inhibitors. Both four-domain (D1-4) and two-domain (D1D2) sCD4 and their fusion proteins have been tested as candidate therapeutics in animal models and in human clinical trials and were well tolerated by patients with no significant clinical or immunologic...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Prabakaran Ponraj

Keywords(s): CD4, entry inhibitor, HIV, MHCII, soluble expression

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Renal Selective Unsaturated Englerin Analogues

Abstract: Englerin A, a natural product, has shown growth-inhibiting activity against renal cancer cell lines. The compound is an agonist of protein kinase C (PCK) theta, which results in cell cytotoxicity, insulin inhibition, and selective activation of viral replication in T cells. Englerin A derivatives are promising treatment strategies for any...

Published: 4/8/2024 | Inventor(s): John Beutler, Tanya Ransom, Antonio Echavarren, Frederic Ratel

Keywords(s): Beutler, DIABETES, HIV, renal cancer, small molecule

Category(s): TherapeuticArea > Endocrinology, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility

Abstract: Griffithsin is a potent anti-viral protein with activity against HIV, HCV, Sars, HSV 1 & 2 and other viruses. It is active against HIV and HCV at picomolar concentrations. Griffithsin is moving into clinical trials as an anti-HIV microbicide. Based on the structure of griffithsin and the necessities of pharmaceutical product development...

Published: 7/16/2024 | Inventor(s): Barry O'Keefe, Kenneth Palmer, Tinoush Moulaei, Lisa Rohan, Joshua Fuqua, Lindsay Kramzer

Keywords(s): Anti-Viral, cnidarin, Griffithsin, HCV, HIV, HSV, SARS

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response

The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy...

Published: 5/22/2024 | Inventor(s): Barbara Felber, George Pavlakis

Keywords(s): CANCER VACCINE, DNA vaccine, ENV, Felber, GAG, HIV, Infectious Disease, Nci, Pavlakis, RNA Vaccine, SARS-CoV-2, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines, TherapeuticArea > Infectious Disease

1 2 3 4